Clinical Evidence Requirements for Philippines Class B, C and D Devices

1. Key takeaways

CMDR applications for Class B, C and D devices require clinical evidence, and the required depth rises with the risk class. Class A notifications normally do not require clinical study data, since the file concentrates on the device description, the Declaration of Conformity, the Declaration of Shelf Life, reference country evidence and labelling — although the FDA may still request supplementary material where it considers this necessary.

GRZAN note: the concept that causes the most confusion is the difference between clinical evidence and a clinical trial. Most mature device categories satisfy the requirement without running a study at all, using literature and equivalence instead. The framework can be remembered as 3 evidence routes, 1 comparison table that decides the equivalence route, and 2 parallel approval tracks where a local study becomes unavoidable.

• Clinical evidence is required for Class B, C and D, scaling with class;
• Class A notifications normally rely on description, declarations, reference evidence and labelling;
• Three routes exist: equivalence, literature review and local clinical study;
• A local study requires CIA approval and ethics review before it can begin.

The commercial consequence of choosing the wrong route is large. Equivalence and literature work are desk exercises that can be completed alongside dossier drafting, whereas a local study introduces an approval sequence, an ethics sequence and a safety reporting sequence, each of which has its own clock and none of which compresses simply because the registration project is late.

2. Legal basis

The dossier requirement, the fast-track condition and the rules governing clinical investigation are summarised below. The investigation rules are at draft stage, but they already indicate the structure that a local study would have to follow, which is why they belong in the planning discussion rather than in a later phase.

3. Expert insights

Insight 1: clinical evidence is not the same thing as a clinical trial. This is the most frequently conflated pair of concepts in the field. Clinical evidence can be built along three routes: comparison of literature and data for an equivalent device, a clinical literature review of an already marketed product, or a clinical study conducted on the device itself. Most established categories are satisfied by the first two. Only where evidence cannot be established through equivalence is a local study in the Philippines required — and that triggers the full sequence of CIA approval and ethics review, with cost and timeline accounted separately.

Insight 2: the equivalence argument succeeds or fails on the comparison table. The core of the equivalence route is demonstrating that the declared device is substantially equivalent to a marketed comparator in technical characteristics, intended use and biological characteristics, and that any differences do not affect safety or effectiveness. Experience shows that the comparison should be built as an item-by-item parameter table covering material, dimensions, performance specifications, indications, method of use and sterilisation method, with each difference accompanied by an argument as to why it does not affect safety or effectiveness. A general statement that the device is essentially the same as the comparator will almost certainly attract a deficiency.

Insight 3: where a local study is unavoidable, approval and registration run on parallel tracks. Conducting a clinical investigation in the Philippines requires a CIA (Clinical Investigation Approval) first. Ethics review is tiered by the number of sites: studies at 1–2 sites go to a PHREB Level III accredited REC, while 3 or more sites require SJREB. Safety reporting duties also apply: serious adverse events must be reported within no more than 7 calendar days of the sponsor first becoming aware, and device deficiencies within no more than 15 calendar days. These obligations run alongside the product registration line and must be scheduled separately rather than folded into a single timeline.

Insight 4: an approval in another ASEAN member state substantially reduces the evidence burden. On the Abridged pathway the FDA takes account of assessments already completed by an ASEAN national regulatory authority. Evidence already accepted in another ASEAN market therefore does not have to be rebuilt from scratch for the Philippines. This is another illustration of the value in obtaining a first ASEAN approval using the CSDT.

4. Practical recommendations

• Attempt the equivalence route first. Build an item-by-item parameter table and argue each difference explicitly.
• Make the literature review systematic. Define the search strategy, inclusion and exclusion criteria and the derivation of conclusions rather than listing papers.
• Treat a local study as the last resort. Where it is unavoidable, calculate the CIA and ethics review timeline and cost before committing.
• Preserve a complete evidence chain. The clinical evaluation report should trace every conclusion back to a source of raw data.

The ordering matters because the three routes are not equally reversible. A weak equivalence table can be strengthened by adding parameters and arguments; a literature review can be rebuilt with a better protocol; but once a local study has started, its schedule is governed by approvals, enrolment and reporting duties that no amount of drafting effort can shorten.

5. Verification checklist

• □ Device class confirmed, since it sets the depth of evidence required
• □ Evidence route selected: equivalence, literature or local study
• □ Equivalence table itemised with parameters and a difference argument for each
• □ Literature review methodology documented, including search strategy and inclusion criteria
• □ Where a local study is required, CIA approval and the correct ethics review tier identified
• □ Every conclusion traceable to a source of raw data

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including the Philippines. Our team prepares CMDN/CMDR dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the FDA Philippines, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com